Sales of Enbrel and Otezla in focus for Amgen's Q2 result
JHVEPhoto/iStock Editorial via Getty Images


Amgen (NASDAQ:AMGN) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close.
The consensus EPS Estimate is $4.33 (-1.1% Y/Y) and the consensus Revenue Estimate is $6.53B (flat Y/Y).
Over the last 2 years, AMGN has beaten EPS estimates 88% of the time and has beaten revenue estimates 75% of the time.

Over the last 3 months, EPS estimates have seen 8 upward revisions and 7 downward. Revenue estimates have seen 8 upward revisions and 3 downward.


In Q1, the company narrowly exceeded Street forecasts for revenue as sales volumes surged ~9% YoY.
But, Sales from Rheumatoid arthritis drug Enbrel fell ~7% YoY to $862M, while plaque psoriasis pill Otezla added $451M sales with a ~7% YoY decline.
For 2022, Amgen revised the GAAP EPS guidance to $12.53 â $13.58 and kept the revenue and non-GAAP guidance unchanged at $25.4B â $26.5B and $17.00 â $18.00 compared to ~$26.22B and $17.40 in the consensus, respectively.
(AMGN) has risen 9.7% YTD.